The most common event type leading to discontinuation was gastrointestinal adverse reactions reported in 3.4% with Wegovy pill and 2% with placebo
Niet bestemd voor personen onder de leeftijd van 18. Bewaar op een koele, droge plaats
GLP-1 weight loss drugs could increase risk of osteoporosis and gout, new research finds Bookmark CommentsGo to comments Taking popular GLP-1 class weight loss drugs like Ozempic and Wegovy could be linked to a higher risk of developing osteoporosis, gout and a condition that causes severe bone softening compared to people who dont use the medications, researchers said Monday
The potential value of combining these therapies lies in addressing overlapping cardiorenal and metabolic risk pathways as available evidence for dual therapy in HF populations remains limited and is derived largely from subgroup analyses, observational studies, and extrapolation from diabetes or obesity trials rather than dedicated HF randomized trials [24, 25, 27, 30, 50]
Jerry RG, Jeffrey WM, Julia MK, Elana H, Julie HS, Gregory SC, et al
Long-chain Acyl-CoA synthetase 4-mediated fatty acid metabolism sustains androgen receptor pathway-independent prostate cancer